In the golden autumn season, experts from across the Taiwan Strait gathered in Zhuhai. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, on August 21–22, bringing together hematology experts and scholars from both sides of the Taiwan Strait, as well as Hong Kong and Macao, for in-depth discussions on cutting-edge developments, clinical practice, and innovations in nursing. During the conference, Oncology Frontier – Hematology Frontier invited Ms. Huiju Tsai of National Taiwan University Hospital to share her perspectives on cross-Strait exchanges in hematology nursing, the application of digital tools in the comprehensive management of hematopoietic stem cell transplantation patients, and prospects for future collaboration in nursing between the two sides.

Transfusion medicine is an essential foundation for the diagnosis and treatment of hematologic diseases, and its underlying philosophy is undergoing a profound transformation from a “blood-centered” to a “patient-centered” approach. As the field advances standardized blood utilization and transfusion safety, how to establish a scientific blood management system and implement precision transfusion strategies remains a key clinical challenge. During the 2026 Cross-Strait Hematology Academic Conference, Oncology Frontier – Hematology Frontier invited Dr. Sheng‑Hsuan Chien of Taipei Veterans General Hospital to systematically review the evolution of transfusion medicine and practical experience from Taiwan, provide an in-depth interpretation of the core principles and precision transfusion pathways of patient blood management (PBM), and explore future directions for collaboration between the two sides of the Taiwan Strait in transfusion quality control, standardized blood utilization, and PBM system development. His insights provide valuable guidance for optimizing clinical blood management.

The “Gaobo Medical Forum—6th Clinical Application Seminar and Training Course on Autologous Hematopoietic Stem Cell Transplantation,” hosted by the National Clinical Research Center for Hematologic Diseases of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and organized by Shanghai Zhaxin Hospital/Gaobo Medical Group and Shanghai Liquan Hospital, was held in Shanghai on August 29–30, 2026. During the meeting, Oncology Frontier – Hematology Frontier invited Dr. Su Li, Director of the Department of Hematology and Director of the Myeloma Center at Gaobo Shanghai Liquan Hospital, to discuss new advances from his team's work in immunotherapy for relapsed/refractory multiple myeloma (RRMM). Dr. Li provided an in-depth analysis of the mechanisms and clinical benefits of BCMA/GPRC5D dual-target CAR-T therapy and shared valuable clinical insights into optimizing combination treatment pathways and refining precision risk stratification.

The 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting will be held in Jinan, Shandong, from September 16 to 19, 2026. As one of China's most important annual academic events in oncology, the CSCO Annual Meeting continues to focus on the international frontiers of oncology research and the needs of clinical practice in China. Experts and scholars from China and abroad will gather to engage in in-depth discussions on key topics including standardized diagnosis and treatment, cutting-edge innovation, and clinical research. Through guideline updates, academic presentations, continuing medical education, and other multidimensional programs, the meeting aims to facilitate the integration of the latest research findings into clinical practice.

On August 29–30, 2026, the "Gaobo Medical Forum — 6th Symposium on the Clinical Application of Autologous Hematopoietic Stem Cell Transplantation and Training Course on the Clinical Application of Autologous Hematopoietic Stem Cell Transplantation," hosted by the National Clinical Research Center for Blood System Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and organized by Gaobo Medical Group's Zhaxin Hospital/Shanghai Liquan Hospital, was held in Shanghai. During the Shanghai conference, Oncology Frontier – Hematology Frontier invited Professor Jun Zhu of Gaobo Shanghai Zhaxin Hospital/Shanghai Liquan Hospital for an in-depth discussion on the clinical positioning and key challenges of autologous hematopoietic stem cell transplantation in the era of novel therapies, as well as a systematic overview of comprehensive management strategies for hemophagocytic lymphohistiocytosis (HLH), providing valuable practical guidance for precision transplantation decision-making.

In the golden autumn season, experts from across the Taiwan Strait gathered in Zhuhai. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, on August 21–22, bringing together hematology experts and scholars from both sides of the Taiwan Strait, as well as Hong Kong and Macao. The conference focused on cutting-edge developments and key areas of clinical practice, facilitating in-depth academic discussions and technical exchanges. A dedicated nursing session was held, featuring senior nursing experts from National Taiwan University Hospital (NTUH), who shared their clinical experience and provided a valuable platform for mutual learning, communication, and collaborative advancement in hematology nursing across the Taiwan Strait. During the conference, Oncology Frontier – Hematology Frontier invited Ms. Xia Yan from Peking University People's Hospital and Ms. Huiru Tsai from National Taiwan University Hospital to engage in an in-depth discussion on topics including the development of dedicated ICUs for hematology patients, infection prevention and control during CAR-T therapy followed by transplantation, and practical details of nursing care in laminar-flow rooms. Their discussion is summarized below for our readers.

The “Gaobo Medical Forum—6th Clinical Application Seminar and Training Course on Autologous Hematopoietic Stem Cell Transplantation,” hosted by the National Clinical Research Center for Hematologic Diseases of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and organized by Shanghai Zhaxin Hospital/Gaobo Medical Group and Shanghai Liquan Hospital, was held in Shanghai on August 29–30, 2026. During the meeting, Oncology Frontier – Hematology Frontier invited Dr. Shan Shao, Medical Team Leader at Gaobo Shanghai Zhaxin Hospital, to systematically discuss alternative treatment strategies for patients intolerant to calcineurin inhibitors (CNIs), drawing on the center's extensive clinical experience, and to share emerging explorations of anti-CD25 monoclonal antibodies as alternatives to CNI and short-course methotrexate (MTX) for GVHD prophylaxis.

The “Gaobo Medical Forum—6th Clinical Application Seminar and Training Course on Autologous Hematopoietic Stem Cell Transplantation,” hosted by the National Clinical Research Center for Hematologic Diseases of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and organized by Shanghai Zhaxin Hospital/Gaobo Medical Group and Shanghai Liquan Hospital, was held in Shanghai on August 29–30, 2026. During the meeting, Oncology Frontier – Hematology Frontier invited Dr. Huixia Liu, Director of the Transplant Ward at Gaobo Shanghai Zhaxin Hospital, to provide a comprehensive analysis and share clinical experience on the challenging issue of allogeneic transplantation for older patients with acute leukemia, covering patient assessment, optimization of conditioning regimens, and post-transplant management.

TP53-abnormal B-ALL is widely recognized as one of the highest-risk and most refractory subtypes of B-ALL. Not only is it highly resistant to conventional chemotherapy, but it is also particularly prone to antigen escape and early relapse following immunotherapy, posing major challenges in clinical management. During the 2026 Cross-Strait Hematology Academic Conference, Oncology Frontier – Hematology Frontier invited Professor Xiaowen Tang from the First Affiliated Hospital of Soochow University to provide a systematic interpretation of the tumor biological characteristics and high-risk factors of TP53-abnormal B-ALL. Professor Tang also discussed strategies for optimizing CAR-T therapy through lymphodepletion regimen optimization and multi-target design, as well as the comprehensive management pathway involving bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT), and looked ahead to future breakthroughs in precision risk stratification, relapse prediction, and integrated treatment.TP53-abnormal B-ALL is widely recognized as one of the highest-risk and most refractory subtypes of B-ALL. Not only is it highly resistant to conventional chemotherapy, but it is also particularly prone to antigen escape and early relapse following immunotherapy, posing major challenges in clinical management. During the 2026 Cross-Strait Hematology Academic Conference, Oncology Frontier – Hematology Frontier invited Professor Xiaowen Tang from the First Affiliated Hospital of Soochow University to provide a systematic interpretation of the tumor biological characteristics and high-risk factors of TP53-abnormal B-ALL. Professor Tang also discussed strategies for optimizing CAR-T therapy through lymphodepletion regimen optimization and multi-target design, as well as the comprehensive management pathway involving bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT), and looked ahead to future breakthroughs in precision risk stratification, relapse prediction, and integrated treatment.